3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
5
Ovarian Neoplasms
3
Neoplasm Metastasis
3
Carcinoma, Non-Small-Cell Lung
3
Neoplasms
2
Lung Neoplasms
2
Lethal Congenital Contracture Syndrome 2
2
Head and Neck Neoplasms
2
Fibromatosis, Gingival, 2
2
Fallopian Tube Neoplasms
2
Colorectal Neoplasms
2
Uterine Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Sarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Kidney Neoplasms
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Ovarian Epithelial
1
Bile Duct Neoplasms
1
Adenocarcinoma
1
Interventions
Gemcitabine
14
Cisplatin
13
Capecitabine
11
Oxaliplatin
9
Fluorouracil
9
130-nm albumin-bound paclitaxel
9
Paclitaxel
8
pembrolizumab
7
Ramucirumab
6
Leucovorin
6
Carboplatin
6
Bevacizumab
6
Albumin-Bound Paclitaxel
6
Pemetrexed
4
Nivolumab
4
Irinotecan
4
Everolimus
4
Erlotinib Hydrochloride
4
Docetaxel
4
Cyclophosphamide
4
trastuzumab deruxtecan
3
Radiotherapy
3
Afatinib
3
zolbetuximab
2
pralsetinib
2
cabozantinib
2
Trastuzumab
2
Ipilimumab
2
vosaroxin
1
vandetanib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Adenocarcinoma
×
seribantumab
×
Clear all
NCT02387216
2021-10-12
SHERLOC
Elevation Oncology
Phase 2
Terminated
153 enrolled
19 charts